Professor Michael D Feher
Professor Michael D Feher is Consultant Physician in Diabetes and Clinical Pharmacology at the Chelsea & Westminster Hospital, London, and Visiting Professor within Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford.
He has had extensive clinical experience in diabetes, lipids and hypertension, combining clinical pharmacology, pharmaco-epidemiology and laboratory-based research with diabetes clinical care and teaching. Publications include eight books in diabetes and cardiovascular medicine.
He is an independent diabetes assessor to London Metropolitan/Home County Police. Committee membership of Heart UK, European Medicines Agency (EASD Diabetes representative and special advisory panel) and Secretary State for Transport Honorary Medical Advisory Panel (DVLA) panel for Driving and Diabetes. He is on the Editorial Board of the British J of Diabetes.
Dr. David Hopkins
Dr Hopkins is a Consultant Physician and Diabetologist. He is Clinical Director for King's diabetes service and Joint Clinical Academic Lead across King's Health Partners. Dr Hopkins leads one of the largest specialist diabetes teams in the UK. He conducts a wide range of specialist diabetes clinics including insulin pump management, diabetic nephropathy, autonomic neuropathy and gastrointestinal complications of diabetes. He qualified in medicine from Liverpool University and subsequently, trained in diabetes, endocrinology and internal medicine in Liverpool (1987-1995) and at King's (1995-1999) where he was a clinical academic group lead in 2014. Dr Hopkins was first appointed as a consultant at Central Middlesex Hospital in 1999 before returning to King's as a consultant in 2004. He became clinical director of the service in 2010 and clinical academic group lead in 2014. Dr Hopkins has broad research interests include management of hypoglycaemia, outcomes of structured patient education in type 1 diabetes and early detection of coronary artery disease in type 2 diabetes. He has national roles as a member of the Diabetes UK Council of Health Professionals and of the DAFNE executive. He acts as audit and quality assurance lead for the national DAFNE structured education programme.
Type 1 diabetes. Insulin pump treatment. Type 2 diabetes and complications
Diabetic kidney disease. Diabetic neuropathy. Gastrointestinal complications of diabetes. Diabetes management following bariatric surgery.
Dr. Stephen Thomas
Dr Stephen Thomas: Consultant in Diabetes and Endocrinology, Guy’s and St Thomas’s NHS Foundation Trust and Clinical Director of the London Clinical Networks. He is also the clinical academic group (CAG) co lead
The London Clinical Networks bring stakeholders together – providers, commissioners and patients – to create alignment around programmes of transformational work that will improve care for the 8+ million residents of the capital. The networks provide the clinical expertise and leadership to drive commissioning decision making. Working across the boundaries of commissioning and provision, they provide a vehicle for improvement, ensuring quality outcomes and value for money, where a single organisation, team or solution could not.
The vision of the London Clinical Networks is to create a system of clinical leadership linking health and social care for consistent, high quality, efficient and evidence-based care for the health and well-being of the capital.
The Clinical Networks, together with the London Clinical Senate and the three Academic Health Science Networks, create a collaborative approach to improvements and innovation in the capital. Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services (DENOVARS)
Diabetes, Endocrinology, Nutrition, Obesity, Vision and Related Services (DENOVARS) Clinical Academic Group (CAG) comprises the largest centre for metabolic disease in Europe.
The CAG brings together a range of services including newly diagnosed Type 1 and 2 diabetes, diabetic eye complication screening, liaison psychiatry, pre-pregnancy care, a full range of podiatric services and treatments, supportive orthotic services, educational programmes for diabetes management, islet transplantation, Dose Adjusted for Normal Eating (DAFNE) programme for Type 1 diabetes, insulin pump therapy and lipid management which provide specialist support for diabetes in every practice in Lambeth and Southwark, and many in Wandsworth.
Professor Roy Taylor
Professor Roy Taylor qualified in medicine at the University of Edinburgh and is Professor of Medicine and Metabolism at Newcastle University and Honorary Consultant at Newcastle Hospitals NHS Trust. He has been conducting research on type 2 diabetes since 1978 and has used a wide range of methods to understand the condition. He created the Newcastle Magnetic Resonance Centre in 2006 and has focussed on how food is handled by the body in health and disease. Recently he has demonstrated that type 2 diabetes can be reversed to normal by decreasing liver and pancreas fat content.
Professor Taylor developed the system now used through the United Kingdom for screening for diabetic eye disease and has demonstrated reduction in blindness rates in Newcastle. He has produced books and other teaching aids for retinal screeners and co-founded the British Association of Retinal Screeners. He has delivered several named lectures to the Annual Professional Meetings of Diabetes UK including the RD Lawrence, Arnold Bloom, Harry Keen Rank Nutrition and Banting Memorial Lectures.
Professor Steve Bain
Professor Steve Bain is Assistant Medical Director for Research & Development for ABM University Health Board and Clinical Lead for the Diabetes Research Network, Wales.
After undergraduate training at St John's College, Cambridge, he was clinically trained at King's College Hospital, London. Qualifying in 1983, he held junior appointments in London, East Midlands, and West Midlands. His research centred on the genetics of type 1 diabetes, and he was granted a Medical Research Council Lectureship. In 1993, he became a Senior Lecturer/Honorary Consultant Physician at Birmingham Heartlands Hospital, with promotion to Reader in Diabetic Medicine in 1998. Professor Bain became a Fellow of the Royal College of Physicians, UK, in 1996 and was appointed to a newly created Chair in Medicine (Diabetes) at Swansea University in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Principal Investigator for several multi-centre trials investigating novel therapies for diabetes.
As a result of his genetics background, Professor Bain became a member of the inaugural West Midlands Multicentre Research Ethics Committee (MREC) and joined the UK Human Genetics Commission. From 2003-2008 he was HGC’s nomination on the National DNA Database Strategy Board and led the HGC report on DNA testing in 2009. In 2007 he was invited to sit on the newly formed National DNA Database Ethics Group, established by the Secretary of State for the Home Department. Professor Bain is Diabetes Lead Clinician for ABM University Health Board, a member of the Wales Diabetes & Endocrine Society (WEDS) executive committee and chairs the Specialist Training Committee for Diabetes & Endocrinology for Wales. He is also on the Board which oversees the ILS Joint Clinical Research Facility, the premier clinical research institute in Wales and is Clinical Director of the Academic Health Science Collaboration for Wales.
Dr. Handrean Soran
Dr. Handrean Soran, MSc, MD, FRCP, is a consultant physician and endocrinologist with a specialist interest in lipidology, parathyroid, calcium and bone metabolism. He received his MRCP diploma from the Royal College of Physicians Edinburgh in 1998, his MSc in diabetes and endocrinology from the University of Liverpool in 2006 and his MD in medicine from the University of Manchester in 2011.
Dr. Soran received his specialist training certificate in endocrinology and diabetes in 2006 and was elected as a fellow of the Royal College of Physicians Edinburgh in 2009. He currently provides a tertiary center lipoprotein disorder service as well as calcium and metabolic bone disease services. He leads the Cardiovascular Trials Unit at the Central Manchester University Hospitals NHS Foundation Trust and the University of Manchester’s lipoprotein research team. His research work is mainly based on cardiovascular risk, LDL quality, HDL functionality and obesity.
Dr Soran acted as the UK chief investigator for more than 15 clinical trials and principal investigator for more than 20 clinical trials and studies. He also acted as a member of the steering committee of many large multinational randomised control trials. He is currently a member of the steering committee of two RCTs and the executive committee of the European Atherosclerosis Society’s Familial Hypercholesterolaemia Collaborative Studies (FHSC).
Dr. Soran is the endocrinology and diabetes education lead for North West Deanery, UK; Royal Society of Medicine lipid and vascular section president and chair of the HEARTUK’s medical, scientific and research committee.
Professor Stephanie Amiel
Professor Stephanie Amiel is an experimental medicine researcher and a clinical diabetes physician. Stephanie uses multiple methods to investigate clinical problems in diabetes therapies, including hypoglycaemia in insulin therapy, the role of the brain in the control of peripheral metabolism, and the impact of black African ethnicity on the metabolic derangements that lead to type 2 diabetes. Stephanie works collaboratively with colleagues in neuroimaging, nutrition, psychology and education and transplantation to improve outcomes particularly for adults with type 1 diabetes. With Sheffield and North Tyneside, and nursing colleagues from King's College Hospital, She led the King's team in the development of the patient education programme DAFNE, still the only such programme in the UK that is NICE-approved. "We continue to work on improvements to the original curriculum. With the King's Liver teams, we also developed islet transplantation at King's for adults with type 1 diabetes and treatment-resistant hypoglycaemia. Physiological and neuroimaging studies followed by qualitative work with people with diabetes led us to conclude that cognitive barriers to hypoglycaemia avoidance may contribute to high risk of severe hypoglycaemia during insulin therapy and we are now running a multi-centre RCT of a novel intervention using cognitive approaches for people who struggle to avoid recurrent severe hypoglycaemia in the management of their type 1 diabetes."
Professor Amiel is a founder member of the International Hypoglycaemia Study Group, which first set out the now widely adopted definitions of hypoglycaemia in diabetes; participated in the development of international guidelines for the use of metabolic surgery in type 2 diabetes and the use of continuous glucose monitoring in improving diabetes outcomes and chaired the NICE guideline development group for the most recent clinical guideline in the diagnosis and management of type 1 diabetes in adults. Stephanie is chairman of the Strategic Research Advisory Group for Diabetes UK and am part of the EU IMI initiative HypoRESOLVE, seeking to define hypoglycaemia in terms of its impact on patients' lives. Stephanie is a mentor on the European Federation for the Study of Diabetes (EFSD) research mentorship programme and sit on its panel.
Professor Amiel current research is funded by Juvenile Diabetes Research Foundation, Diabetes UK and the EU.
Dr. Emma Wilmot
Emma Wilmot is a Consultant Diabetologist at University Hospitals of Derby and Burton NHS Foundation Trust. Her specialist interests include Type 1 diabetes, insulin pump therapy and diabetes technology, young adults with diabetes and antenatal diabetes care.
She was awarded the University of Leicester medal for excellent PhD performance in 2013 for her PhD “Type 2 diabetes in younger adults” and was appointed as an Honorary (consultant) Assistant Professor at the University of Nottingham in 2018. She is principal investigator on several diabetes research trials.
She is founder of the ABCD Diabetes Technology Network UK. As chair she previously led the delivery of educational events for multidisciplinary diabetes teams and the development of national insulin pump ‘best practice’ guides, in addition to online modules for people living with diabetes. Emma is an elected Association of British Clinical Diabetologists (ABCD) committee member and DAFNE structured education executive board member. She is a member of the National Diabetes Audit Insulin Pump Expert Reference Group and has also been involved in the #languagematters movement.
Professor Richard M. Bergenstal
Richard M. Bergenstal, MD, is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. He is Clinical Professor in the Department of Medicine at the University of Minnesota and served as President, Science & Medicine of the American Diabetes Association in 2010. In 2007, Dr. Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year and in 2010 he was awarded the Banting Medal for Service for outstanding leadership and service to the American Diabetes Association.Dr. Bergenstal received his MD and endocrine training from the University of Chicago where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983.His clinical research has focused on glucose control and diabetes complications and he serves as a Principal Investigator of three NIH trials: the Diabetes Control and Complications Trial (DCCT) in type 1 diabetes and the Action to Control Cardiovascular Risks in Diabetes (ACCORD) study and the Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) study in type 2 diabetes.
Dr. Bergenstal’s clinical efforts have been directed toward improving systems of care for patients with diabetes by translating new research findings in to practice. He studies the effective utilization of insulin therapy and glucose monitoring (SMBG and CGM) to improve glucose control and clinical outcomes. He teaches nationally and internationally on the importance of patient-centered team care, has been listed in Best Doctors in America since it began in 1992, has published over 100 peer reviewed scientific articles in diabetes and has co-authored the best selling Betty Crocker Diabetes Cookbook.
Dr. Mahmoud Barbir
Dr Mahmoud Barbir is a consultant cardiologist at Royal Brompton and Harefield Hospital NHS Foundation Trust, and also Honorary Senior Lecturer in Clinical Cardiology and Imaging NHLI. Dr Barbir is the Lead Physician of the largest lipoprotein apheresis centres in the UK. He acted as a member of the working group the National Institute for Health & Care Excellence Development Group on clinical guidelines for the management of familial hypercholesterolaemia and lipoprotein apheresis. Dr Barbir is a member of the Working Group HEART UK on lipoprotein apheresis. He graduated in 1980 from the Royal College of Surgeons in Ireland. He did his initial training in general medicine and cardiology in Dublin, at St James's Hospital, Dr Steven’s Hospital and St Laurence's Richmond Hospital, Dublin.
In 1985, Dr Barbir came to London and started a British Heart Foundation research fellowship at Hammersmith Hospital for two years. He subsequently completed three years training in clinical cardiology.
Then in 1988, he completed clinical research at Harefield Hospital working under Professor Sir Magdi Yacoub. Meanwhile, he completed further training in the department of cardiology. In 1993, he became a consultant.
Specialist and research interests:
Cardiovascular risk factors. Dyslipidaemia including Lipoprotein(a). Familial hypercholesterolaemia. Lipoprotein apheresis and PCSK9 monoclonal antibodies. Ischaemic heart disease. Transplant related coronary artery disease.
Professor Michael Edmonds
Michael Edmonds is a Consultant Physician at King’s College Hospital in London with a special responsibility for care of the diabetic foot. He developed a multi-disciplinary diabetic foot clinic in 1981, one of the first in the world. This clinic brought about a 50% reduction in major amputations in people with diabetes at King’s College Hospital. He is a past Chairman of the Diabetic Foot Study Group of the European Association of the Study of Diabetes. He has co-authored the book Managing the Diabetic Foot (Blackwell Science) and A Practical Manual of Diabetic Foot Care (Blackwell Science), which was voted BMA Book of the Year in 2004. He won the Karel Bakker award at the 6th International Symposium on the Diabetic Foot in 2011 and more recently in 2013 the DFSG Achievement Award. He has also won the Edward James Olmos award for the advocacy in amputation prevention at the DF Con 2014 and gave the Arnold Bloom lecture at Diabetes UK in 2015.
Dr. Parth Narendran
Parth is a qualified clinician by background. His research is primarily on type 1 diabetes, in particular on how to preserve the function of insulin producing pancreatic beta cells. Parth undertook his initial immunology research training as part of an intercalated degree. This led to a PhD at the University of Bristol exploring peptide immunotherapy for type 1 diabetes, and subsequently to a post-doctoral fellowship exploring immune tolerance at the Walter and Eliza Hall Institute in Melbourne.
Parth obtained his basic medical degree in London before completing his higher specialist training in Manchester and Bristol. He took up his current post as an Honorary Consultant Physician at The Queen Elizabeth Hospital, Birmingham in 2005.
He is currently the co-lead for the West Midlands Clinical Research Network and was previously the diabetes theme lead for the Birmingham and Black Country Clinical Research Network from 2010-14. He leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 50 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He currently sits on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.
Dr. Samantha Mann
Samantha Mann has been a consultant ophthalmologist at Guy’s and St Thomas’ Hospital since 2009. She previously trained as a registrar at Moorfields Eye Hospital and the Royal Free Hospital in North London following completion of an MD in the Phenotyping of Age-related Macular Degeneration whilst a clinical fellow at the Institute of Ophthalmology and Moorfields Hospital.
She is one of three medical retinal consultants leading a busy unit seeing and treating over 300 patients a week with conditions including diabetic retinopathy, macular degeneration, retinal vein occlusions, genetic eye disease and central serous retinopathy.
Over the past nine years, she has developed a special interest in diabetes and diabetic eye screening at St Thomas’ and is the clinical lead for this service covering 100,000 patients in the south east London region. She is constantly striving to improve the quality of the service further and has been actively involved in compiling the London OCT scanning protocol for use within diabetic eye screening surveillance pathways.
Additionally, she has several publications on age-related macular degeneration and diabetic eye screening including the production of a video called 'Danny’s Story' which tells the story of a young male with diabetes blinded through failure to attend his screening appointments.
Philip Newland-Jones is a Consultant Pharmacist in Diabetes and Endocrinology and has worked at University Hospitals Southampton NHS Foundation Trust since 2008. He is a current committee member of the UKCPA Diabetes and Endocrinology Group and Chairs the regional Diabetic subgroup of the District Prescribing Committee. At Southampton he takes a leading role in the trust’s patient improvement framework for diabetes with numerous patient safety projects previously undertaken and ongoing. At a national level he is the lead pharmacist for NHS England Diabetes Clinical Reference Group and sits on the diabetes parliamentary think tank. He has a key role with pharmaceutical input into the direction of inpatient diabetes care at University Hospital Southampton and works in a specialist practitioner role on a day to day basis reviewing in patients with diabetes issues. His dedication to education ensures the rest of his time is taken up educating doctors, nurses, allied healthcare professionals and students within secondary care, primary care and university settings.
Dr. Naresh Kanumilli
Naresh is a GP in a large practice in South Manchester and has been the GPwSI in Manchester for over 12 years. He is also the Long-Term Conditions Lead for South Manchester CCG and has been involved in the development of services and protocols to improve the outcomes for people with diabetes.
At the CCG level Naresh believes in improving the knowledge of both people with diabetes and the healthcare professionals managing diabetes. Currently in his role as the strategic clinical network lead, he is helping CCGs to understand the importance of the NDA and looking at avenues to improve the participation and improve outcomes for people with diabetes. The network has also taken on a programme to improve the delivery and uptake of structured education, by looking at the barriers and innovative ways of providing education.
His role as the research lead is to promote research within primary care and to raise awareness amongst patients about the importance and the benefits of taking part in research.
As a Clinical Champion, he will bring together a wide-ranging group of stakeholders, all with the common purpose of improving care and outcomes for people with diabetes across Greater Manchester. This will take significance with the Devolution of health and social care in Manchester. The group includes patient groups and charities all who will work with a common purpose.
Naresh’s motto for people with diabetes is “No Medication without Education”.